Bayesians in clinical trials: Asleep at the switch

Statistics in Medicine

Volumn 27, Issue 4, 2008, Pages 469-482

  Moyé, Lemuel A ^a  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Bayes; Loss functions; Methodology; Prior distributions

Indexed keywords

AMLODIPINE; ENCAINIDE; FLECAINIDE; LOSARTAN; MORACIZINE;

ADULT; AGED; ANALYTICAL ERROR; ARTICLE; BAYES THEOREM; CARDIOLOGY; CLINICAL RESEARCH; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESEARCH; FREQUENCY ANALYSIS; HEART ARRHYTHMIA; HUMAN; MEDICAL RESEARCH; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL DISTRIBUTION; STATISTICAL SIGNIFICANCE;

BAYES THEOREM; BIOMETRY; CLINICAL TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS;

EID: 39449122181     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.2928     Document Type: Article

References (79)

1. Berry DA. A case for Bayesianism in clinical trials (with discussion). Statistics in Medicine 1993; 12:1377-1404.
2. Spiegelhalter DJ, Freedman LS, Parmar MKB. Bayesian approaches to randomized trials (with discussion). Journal of the Royal Statistical Society Series A 1994; 157:357-416.
3. Diamond GA, Kaul S. Prior convictions: Bayesian approaches to the analysis and interpretation of clinical megatrials. Journal of the American College of Cardiology 2004; 43:1929-1939.
4. Spiegelhalter DJ, Freedma LS, Parmar MK. Applying Bayesian ideas in drug development and clinical trials. Statistics in Medicine 1993; 12:1501-1511.
5. Cui L, Hung HMJ, Wang S. Modification of sample size in group sequential clinical trials. Biometrics 1999; 55:853-857.
6. Lehmacher W, Wassmer G. Adaptive sample size calculations in group sequential trials. Biometrics 1999; 55: 1286-1290.
7. Muller H, Schafer H. Adaptive group sequential designs for clinical trials: combining the advantages of adaptive and of classical group sequential approaches. Biometrics 2001; 57:886-891.
8. Proschan MA, Hunsberger SA. Designed extension of studies based on conditional power. Biometrics 1995; 51:1315-1324.
9. Cheng Y, Su F, Berry DA. Choosing sample size for a clinical trial using decision analysis. Biometrika 2003; 90:923-936.
10. Moyé LA. Sizing clinical trials with variable endpoint event rates. Statistics in Medicine 1997; 16:2267-2282.
11. Korn EL, Baumrind S. Clinician preferences and the estimation of causal treatment differences. Statistical Science 1998; 13:209-235.
12. Berry DA. Bayesian statistics and the efficiency and ethics of clinical trials. Statistical Science 2004; 19(1): 175-187.
13. Speigelhalter DJ, Freedman LS, Blackburn PR. Monitoring clinical trials: conditional or predictive power. Controlled Clinical Trials 1986; 7:8-17.
14. Nicholl J, Goodacre S. Bayesian stopping rules for trials. Lancet 2002; 359:76-77.
15. Freedman LS, Spiegenhalter DJ. Comparison of Bayesian with group sequential methods for monitoring clinical trials. Controlled Clinical Trials 1989; 10:357-367.
16. Freeman LS, Spoiegelhbalter DJ, Permar MK. The what, why, and how of Bayesian clinical trial monitoring. Statistics in Medicine 1994; 13:1371-1383.
17. Ashby D, Hutton J, McGee M. Simple Bayesian analysis for case-control studies in cancer epidemiology. The Statistician 1993; 42:385-397.
18. Dunson DB. Practical advantages of Bayesian analysis of epidemiologic data. American Journal of Epidemiology 2001; 153:1222-1226.
19. Kmetic A, Joseph L, Berger C, Tenenhouse A. Multiple imputation to account for missing data in a survey: estimating the prevalence of osteoporosis. Epidemiology 2002; 13:437-444.
20. Berrry DA, Eick SG. Adaptive assignment versus balanced randomization in clinical trials - a decision analysis. Statistics in Medicine 1995; 14:231-246.
21. Berry DA, Müller P, Grieve AP, Smith M, Parke T, Blazek R, Mitchard N, Krams M. Adaptive Bayesian designs for dose-ranging drug trials. Case Studies in Bayesian Statistics V. Lecture Notes in Statistics, vol. 162. Springer: New York, 2002; 99-181.
22. Berry D. A guide to drug discovery; Bayesian clinical trials. Nature Reviews Drug Discovery 2006; 5:27-36.
23. Berger JO. Statistical Decision Theory. Foundations, Concepts, and Methods. Springer: New York, 1980.
24. Carlin BP, Louis TA. Bayes and Empirical Bayes Methods of Data Analysis (2nd edn). Chapman & Hall, CRC Press: London, Boca Raton, 2000.
25. Gelman A, Carlin JB, Stern HS, Rubin DB. Bayes Data Analysis (2nd edn). Chapman & Hall, CRC Press: London, Boca Raton, 2003.
26. Speigelhalter DJ, Abrams, KR, Myles JP. Bayesian Approach to Clinical Trials and Health-Care Evaluation. Wiley: New York, 2004.
27. Stigler SM. The History of Statistics: The Measurement of Uncertainty before 1990. The Belknap Press of Harvard University Press: Cambridge, London, 1986; P98.
28. Zabell S. R.A. Fisher on the history of inverse probability. Statistical Science 1989; 4:247-256.
29. Zabell S. R.A. Fisher on the history of inverse probability. Rejoinder. Statistical Science 1989; 4:261-263.
30. Fisher RA. Statistical Methods For Research Workers. Oliver and Boyd: Edinburg, 1925.
31. Fisher RA. Two new properties of mathematical likelihood. Proceedings of the Royal Society Series A 1934; 144:285-307.
32. Neyman J, Peason ES. On the problem of the most efficient tests of statistical hypotheses. Philosophical Transactions of the Royal Society (London) Series A 1933; 231:289-337.
33. Neyman J, Pearson ES. On the use and interpretation of certain test criteria for purposes of statistical inferences: parts I and II. Biometrika 1933; 20:175-240, 263-294.
34. Pytkowsi W. The Dependence of the Income in Small Farms upon their Area, the Outlay and the Capital Invested in Cows (Polish, English summaries). Monograph Series Bioblioteka Pulawska, No. 31. Publ. Agricultural Research Institute: Pulawy, Poland.
35. Wald A. Statistical Decision Functions. Wiley: New York, 1950.
36. Neyman J. Outline of a theory of statistical estimation based on the classical theory of probability. Philosophical Transactions of the Royal Society (London) Series A 1937; 236:333-380.
37. Neyman J. L'estimation statistique traitée comme un problème classique de probabilité. Actualités Scientifiques et Industriels 1938; 739:25-57.
38. Neyman J, Peason ES. On the problems of most efficient tests of statistical hypotheses. Philosophical Transactions of the Royal Society of London, Series A 1933; 231:289-337.
39. Jeffreys H. Scientific Inference, reprinted with additions in '37 and with new editions in '57 and '73. Cambridge University Press: Cambridge, 1931.
40. Hartigan J. Invariant prior distributions. Annals of Mathematical Statistics 1964; 35:836-845.
41. Dawid P, Stone M, Zidek JM. Marginalization paradoxes in Bayesian and structural inference (with discussion). Journal of the Royal Statistical Society Series B 1973; 35:189-233.
42. Fisher RA. Inverse probability and the use of likelihood. Proceedings of the Cambridge Philosophical Society 1932; 28:257-261.
43. Jeffreys H. On the prior probability in the theory of sampling. Proceedings of the Cambridge Philosophical Society 1933; 29:83-87.
44. Jeffreys H. On the theory of errors and least squares. Proceedings of the Royal Society of London, Series A 1932; 138:48-55.
45. Fisher RA. The concepts of inverse probability and fiducial probability referring to unknown parameters. Proceedings of the Royal Society of London, Series A 1933; 139:343-348.
46. Jeffreys H. Probability, statistics, and the theory of errors. Proceedings of the Royal Society of London, Series A 1933; 140:523-535.
47. Fisher RA. Probability, likelihood and the quantity of information in the logic of uncertain inference. Proceedings of the Royal Society of London, Series A 1934; 146:1-8.
48. Jeffreys H. Probability and scientific method. Proceedings of the Royal Society of London, Series A 1934; 146:9-16.
49. Savage LJ. The theory of statistical decision. Journal of the American Statistical Association 1951; 46:55-67.
50. Savage LJ. The Foundations of Statistics (1972 edn). Wiley: New York, 1954.
51. Tales of Statisticians. LJ Savage (1917-1971). From http://www.umass.edu/ wsp/statistics/tales/savage.html
52. Moyé LA. Statistical Monitoring of Clinical Trials: Fundamentals for Investigators. Springer: New York, 2005.
53. Goodman SN. Toward evidence-based medical statistics. 1: the p-value fallacy. Annals of Internal Medicine 1999; 130:995-1004.
54. Walker AM. Significance tests represent consensus a and standard practice (Letter). American Journal of Public Health 1986; 76:1033 (see also Journal erratum;76:1087).
55. Fleiss JL. Significance tests have a role in epidemiologic research; reactions to A.M. Walker, (Different views) American Journal of Public Health 1986; 76:559-560.
56. Fleiss JL. Confidence intervals versus significance tests: quantitative interpretation (Letter). American Journal of Public Health 1986; 76:587.
57. Fleiss JL. Dr. Fleiss response (Letter). American Journal of Public Health 1986; 76:1033-1034.
58. Walker AM. Reporting the results of epidemiologic studies. American Journal of Public Health 1986; 76:556-558.
59. Pratt JW. Discussion of A. Birnbaum's On the foundations of statistical inference. Journal of the American Statistical Association 1962; 57:269-326.
60. Moyé LA. Statistical Reasoning in Medicine: The Intuitive P-value Primer (2nd edn). Springer: New York, 2006.
61. Ramsey F. Truth and Probability in Ramsey 1931. In The Foundations of Mathematics and other Logical Essays, Chapter VII, Braithwaite RB (ed.), Degan, Paul, Trench, Trubner & Co.: London, Harcourt, Brace, and Company: New York, 1926; 156-198 (1999 electronic edition).
62. The CAST Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. New England Journal of Medicine 1989; 3212:406-412.
63. Moore T. Deadly Medicine. Simon and Schuster: New York, 1995.
64. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study (UKPDS) VIII. Study, design, progress and performance. Diabetologia 1991; 34:877-890.
65. Moyé LA. Multiple Analyses in Clinical Trials: Fundamentals for Investigators, Chapter 8. Springer: New York, 2003.
66. UKPDS Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. The Lancet 1998; 352:837-853.
67. Turner RC, Holman RR on behalf of the UK Prospective Diabetes Study Group. The UK Prospective Diabetes Study. Finnish Medical Society DUOCECIM. Annals of Medicine 1998; 28:439-444.
68. UKPDS Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. The Lancet 1998; 352:837-853.
69. Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepine CJ, Gilbert EM, Strobeck JE, Hendrix GH, Powers ER, Bain RP, White BG for the Vesnarinone Study. Effects of vesnarinone on morbidity and mortality in patients with heart failure. New England Journal of Medicine 1993; 329:149-155.
70. Cohn JN, Goldstein SO, Greenberg BH, Lorell BH, Bourge RC, Jaski BE, Gottlieb SO, McGrew F 3rd, DeMets DL, White BG. A dose dependent increase in mortality seen with vesnarinone among patients with severe heart failure. New England Journal of Medicine 1998; 339:1810-1816.
71. Pitt B, Segal R, Martinez FA et al. on behalf of the ELITE Study Investigators. Randomized trial of losartan versus captopril in patients over 65 with heart failure. The Lancet 1997; 349:747-752.
72. Jensen BV, Nielsen SL. Correspondence: Losartan versus captopril in elderly patients with heart failure. The Lancet 1997; 349:1473.
73. Fournier A, Achard JM, Fernandez LA. Correspondence: Losartan versus captopril in elderly patients with heart failure. The Lancet 1997; 349:1473.
74. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, Neuberg GW, Frid D, Wertheimer JH, Cropp AB, DeMets DL for the Prospective Randomized Amlodipine Survival Evaluation Study Group. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. New England Journal of Medicine 1996; 335:1107-1114.
75. Packer M. Presentation of the Results of the Prospective Randomized Amlodipine Survival Evaluation-2 Trial (PRAISE-2) at the American College of Cardiology Scientific Sessions, Anaheim, CA, March 15, 2000.
76. Egger M, Smith GD, Phillips AN. Meta-analyses: principles and procedures. British Medical Journal 1997; 315:1533-1537.
77. Alderson P, Roberts I. Corticosteroids in acute traumatic brain injury: systematic review of randomised controlled trials. British Medical Journal 1997; 314:1855-1859.
78. Gregson B, Todd NV, Crawford D, Gerber CJ, Fulton B, Tacconi L, Crawford PJ, Sengupta RP. CRASH trial is based on problematic meta-analysis. British Medical Journal 1999; 319:578.
79. Moyé L. Face to Face with Katrina Survivors: A First Responder's Account. Open Hand Publishing: Greensboro, 2006.